Minerva Neurosciences, Inc. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
Minerva Neurosciences, Inc. (NERV) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $4.15 million as of 2020-12-31, per its 10-K filed 2022-03-01.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2022-03-01
- 2020-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $4.15M.
- 2019-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $4.15M.
- 2018-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $9.34M.
- 2017-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $9.34M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2020-12-31 | $4.15M 10-K · filed 2022-03-01 |
| 2019-12-31 | $4.15M 10-K · filed 2021-03-08 |
| 2018-12-31 | $9.34M 10-K · filed 2020-03-09 |
| 2017-12-31 | $9.34M 10-K · filed 2019-03-12 |
| 2016-12-31 | $13.43M 10-K · filed 2018-03-12 |
| 2015-12-31 | $13.43M 10-K · filed 2017-03-13 |
| 2014-12-31 | $13.43M 10-K · filed 2016-03-14 |
| 2013-12-31 | $7.59M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |